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ABSTRACT 
The catecholamines: dopamine, norepinephrine, and epinephrine, are naturally 
occurring amines that function as hormones and neurotransmitters.  Excess 
concentrations of catecholamines have been observed in patients with rare 
neuroendocrine tumors and are associated with chronic hypertension, stroke, myocardial 
infarction, and cardiovascular disease.  These potential consequences of high 
catecholamine concentrations emphasize the need for a rapid and accurate analytical 
measurement method.  Catecholamines are often measured using high performance liquid 
chromatography (HPLC) with electrochemical detection; however, the liquid 
chromatography tandem mass spectrometry (LC-MS/MS) technique is attractive due to 
its selectivity and throughput.  Derivatization of catecholamines prior to LC-MS/MS 
analysis of plasma specimens may be used to enhance assay sensitivity.  The goal of this 
study was to evaluate reductive amination derivatization of catecholamines using 
straight-chain and branched-chain aldehydes as a means to improve the sensitivity of the 
assay. Derivatization was performed on each catecholamine in triplicate using a series of 
straight-chain and branched-chain aldehydes.  Aqueous catecholamine standards were 
reacted with an aldehyde in the presence of a buffer (ammonium acetate) and reducing 
agent (sodium cyanoborohydride) at 37 °C for 30 minutes.  Samples were quenched with 
formic acid at room temperature and injected onto an LC-MS/MS system for analysis.  
Catecholamine derivatives were identified by individual retention times and mass 
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transitions. Peak area counts were determined for three mass transitions for each 
derivative. The six-carbon straight-chain aldehyde, hexanal, and the branched-chain 
aldehyde, hydrocinnamaldehyde, proved to be the most effective derivatizing agents for 
the catecholamines in plasma assay. A derivatization protocol using 
hydrocinnamaldehyde was optimized for aldehyde and reducing agent concentrations, 
and incubation time and temperature.  Derivatization with hydrocinnamaldehyde 
produced single alkylated products for all three catecholamines. Comparison of the 
derivatization agents showed higher peak area counts for norepinephrine and epinephrine 
derivatized with hydrocinnamaldehyde; hexanal provided greater sensitivity for 
dopamine.  A method application experiment on patient samples using 
hydrocinnamaldehyde demonstrated its significant effect on assay sensitivity and 
supports use in a clinical setting.  However, sensitivity for dopamine was inadequate and 
overall accuracy and precision were unsatisfactory.  Further optimization of the 
derivatization protocol using hydrocinnamaldehyde is required to meet acceptable 
analytical criteria for this assay.  
I would like to dedicate this thesis to my amazing mom.  Thank you for your 
words of wisdom and encouragement the last few years.  Without you, this would not be 
possible.  I love you!  
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The catecholamines dopamine (DA), norepinephrine (NOR), and epinephrine 
(EPI) are naturally occurring amines that function as hormones and neurotransmitters 
(Figure 1) (1).  Catecholamines are composed of a catechol (phenyl ring with vicinal 
hydroxyl groups) with an ethylamine chain on the first carbon.  Dopamine has the basic 
structure while norepinephrine and epinephrine are distinguished by additional functional 
groups on the ethylamine chain.  Norepinephrine contains a hydroxyl group on the beta 
carbon of the ethylamine while epinephrine is further distinguished by a methyl group on 
the nitrogen atom.  
These compounds are synthesized from tyrosine via a series of enzymatic 
reactions in the brain, sympathetic nerve fibers, and chromaffin cells of the adrenal 




Figure 1.  Structure of catecholamines 
Catecholamines are composed of a catechol (phenyl with vicinal hydroxyl groups) and an 
ethyl amine chain on the first carbon.  Norepinephrine has a hydroxyl group on the ethyl 




Figure 2.  Synthesis of catecholamines 
Catecholamines are synthesized in a series of enzymatic reactions; tyrosine is 
hydroxylysed to 3, 4-dihydroxyphenylalanine (l-DOPA) by tyrosine hydroxylase, l-
DOPA is decarboxylated to dopamine by aromatic l-amino acid decarboxylase, dopamine 
is hydroxylated to norepinephrine by dopamine-β hydroxylase, and norepinephrine is 
converted to epinephrine by phenylethanolamine N-methyltransferase.  
 
During synthesis, tyrosine is converted to 3, 4-dihydroxyphenylalanine (L-DOPA) 
in a reaction catalyzed by the enzyme tyrosine hydroxylase, L-DOPA is converted to 
dopamine by aromatic L-amino acid decarboxylase, dopamine is converted to 
norepinephrine by dopamine β-hydroxylase, and norepinephrine is converted to 
epinephrine by phenylethanolamine N-methyltransferase (2).  
Due to their structure, catecholamines are categorized as amphoteric (react as an 
acid or base) compounds.  In acidic conditions, the amine groups are protonated while the 
catechol group remains un-charged.  In alkaline conditions, the catechol groups are 
oxidized to quinones making them electroactive.  Catecholamines are also polar and 
hydrophilic.   
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Dopamine has been recognized as an intermediate for the formation of 
norepinephrine and epinephrine (3).  It is abundant in the brain and is mainly responsible 
for initiation and maintenance of movement, alertness, anxiety, vision, and smell. 
Dopamine controls the pleasure centers in the brain, which can have an effect on drug 
addiction.  Dopamine also plays a role in regulation of sodium excretion (4).  
Physiological disorders affecting release and transport of dopamine in the brain have 
been linked to Parkinson disease (4).  It has been suggested that the degeneration of 
dopaminergic neurons in the brain affects communication across the brain, which leads to 
symptoms of Parkinson’s disease (5).   
In some cases, genetic disorders can produce excess dopamine.  For example, 
deficiency of dopamine β-hydroxylase, an enzyme that oxidizes dopamine to 
norepinephrine, leads to excess dopamine and consequently low concentrations or lack of 
norepinephrine and epinephrine.  This condition has been linked to schizophrenia and 
other psychiatric disorders (6).   
Norepinephrine is mainly produced in the sympathetic nervous system and helps 
regulate the physiological functions of several organs in the body.  It plays a role in 
cardiovascular regulation during stress by increasing heart rate, constricting peripheral 
arterioles, dilating skeletal arterioles, and elevating blood pressure.  Norepinephrine 
concentration in plasma depends on the physiological and pathological states of the 
human body.  For example, norepinephrine is produced in large quantities during 
exercise, hypertension, cardiac failure, depression, and during mental stress (4). 
Epinephrine is mainly produced in the chromaffin cells in the adrenal medulla.  It 
is released in stressful situations and plays similar roles as norepinephrine.  Epinephrine 
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is released in larger concentrations in response events including hypoglycemia, 
hypotension, asphyxiation, circulatory response, and distress compared to 
norepinephrine.  This indicates that the adrenal medulla system is greatly activated in 
such events compared to the sympathetic nervous system responsible for norepinephrine 
(7).  It also plays a role in lipolysis (breakdown of fat to generate energy), ketogenesis 
(release of ketones when fat is break down for energy), thermogenesis (burning of 
calories to produce heat), and glycolysis (breakdown of glucose to extract energy), and 
can activate the pulmonary system by dilating the veins (4).  Excess concentrations of 
epinephrine are also observed in Addison’s disease, which is an autoimmune disease 
characterized by an impaired adrenal cortex in the adrenal glands (8).  
Like other hormones, catecholamines are usually metabolized to terminate their 
actions.  Numerous enzymes are responsible for their metabolism, which leads to a 
variety of metabolites.  The primary enzymes involved are monoamine oxidase (MAO), 
catechol-O-methyltransferase (COMT), and alcohol dehydrogenase (ADH).  Dopamine is 
first O-methylated by COMT and later deaminated by MAO to form its final metabolite, 
homovanillic acid (HVA) .  Norepinephrine is O-methylated by COMT to form 
normetanephrine, which is later oxidized by alcohol dehydrogenase (ADH) to form its 
final metabolite vanillylmandelic acid (VMA).  Epinephrine is O-methylated by COMT 
to form metanephrine, which is later metabolized by MAO and ADH to also form VMA 





Figure 3  Metabolism of catecholamines 
COMT and MAO convert dopamine to 3-Methoxytyramine and its final metabolite 
homovanillic acid (HVA), respectively.  COMT and ADH convert norepinephrine to 
normetanephrine and to its final metabolite VMA.  COMT, MAO, and ADH convert 




Excess concentrations of catecholamines have been observed in patients suffering 
from rare neuroendocrine tumors such as adrenal pheochromocytomas that form in the 
chromaffin cells and extra-adrenal sympathetic paragangliomas (PPGLs), which form in 
the extra adrenal tissues of the abdomen, pelvis, and chest.  Pheochromocytomas and 
PPGLs occur in 1-4 patients per 100,000 (2).  Only 10-15% of the tumors are diagnosed 
as malignant while most are benign.  Symptoms associated with excess concentrations of 
catecholamines include headaches, excess sweating, palpitations, and hypertension.  
These tumors are extremely difficult to diagnose as the signs and symptoms are similar to 
those observed in other diseases.  High concentrations of catecholamines over a 
prolonged period can lead to severe health conditions such as chronic hypertension, 
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myocardial infarction, stroke, and cardiovascular disease (2).   
Although measurement of catecholamines in plasma has been used as a screening 
test for pheochromocytomas and PPGLs, this testing is not recommended for initial 
evaluation of a potential tumor.  Catecholamine metabolites such as metanephrine and 
normetanephrine are found in higher concentrations and have a longer half-life (are more 
stable).  Testing of these metabolites is preferred for higher sensitivity and accuracy (1, 
2).   
However, catecholamines assays are still important for the following reasons: as a 
screen for PPGLs that only excrete dopamine (10) which is not metabolized into 
metanephrine or normetanephrine, to evaluate the role of dopamine in development of 
Parkinson’s disease, to screen for dopamine β-hydroxylase deficiency which is associated 
with excess dopamine and low epinephrine and norepinephrine concentrations (4, 5), and 
to provide supplementary information in evaluation of clinical symptoms of excess 
catecholamines (11). In addition, catecholamines play an important role in neuroscience.  
Impaired synthesis, metabolism, and transportation of neurotransmitters, including 
catecholamines, can affect the body’s homeostasis (12).  Catecholamines norepinephrine 
and epinephrine have been explored as possible biomarkers in diseases such as diabetes, 
heart disease, pain, and anxiety (13).  Therefore, the study of catecholamines and their 
metabolites can help in disease diagnosis, neurophysiology, understanding behavioral 
effects, pathology of diseases, and treatment therapies.  These reasons as well as the fatal 
consequences associated with excess concentrations of catecholamines emphasize the 





Measurement of catecholamines 
Measurement of catecholamines (dopamine, norepinephrine, and epinephrine) in 
plasma was previously performed using various analytical methods, including 
fluorometric, spectrophotometric, radioenzymatic, gas chromatography (GC), and high 
performance liquid chromatography (HPLC) techniques.  The method used in most 
clinical laboratories is HPLC with electrochemical detection (HPLC-EC) due to its high 
sensitivity (14).  However, one popular HPLC-EC  method presents multiple challenges 
including large sample volume requirements (> 2 mL), long sample preparation time, and 
a lengthy chromatographic separation time (20-minutes injection-to-injection).  In 
addition, the assay uses alumina at a basic pH (~ 8.5) for optimum sample extraction.  
Catecholamines are readily oxidized at this pH and results may be compromised (14).  
Matrix interferences seen in poorly resolved chromatograms are also a concern.  Due to 
these issues, a method with higher selectivity and throughput is desired for the assay.    
Multiple scientists have suggested that liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) meets the desired criteria for this assay.  Compared to 
electrochemical detection, LC-MS/MS provides more options for chemical analysis in 
terms of mass resolution (selectivity) and throughput.  High selectivity is achieved in the 
mass spectrometer by pairing the retention time, precursor-product mass transitions to 
selectively identify compounds. Multiple reaction monitoring (MRM) is also used in LC-
MS/MS to monitor specific precursor-product mass transitions therefore increasing 
selectivity and accuracy by reducing back ground noise in the detector (10, 11, 14, 15, 
16).  In cases where multiple compounds share similar precursor masses, LC-MS/MS is 
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able to distinguish them bases on their fragmentation patterns (4). 
High throughput catecholamine assays have successfully been developed using 
ultra-performance liquid chromatography (UPLC-MS/MS) instruments. Chengjie et al. 
(2011) reported on a norepinephrine and epinephrine assay using UPLC-MS/MS with an 
(injection-to-injection) time of 3.5 minutes (11).  
In the MRM technique, the sample is injected into the LC column where the 
analytes are separated based on their interaction with the stationery phase.  Once the 
analytes are eluted from the LC column, they are ionized using electrospray ionization 
(ESI) before entering the first quadrupole of the mass spectrometer.  The precursor ion 
(analyte of interest) is identified and directed into the quadrupole collision cell where it is 
fragmented into product ions.  The product ions are directed into the third quadrupole 




Figure 4 – Liquid chromatography mass spectrometry (LC-MS/MS) instrumentation 
Samples are injected into the HPLC pump and separated in the column.  The analytes are 
eluted at different retention times (RT) into the ionization chamber.  Using MRM the 
precursor ion is selected in Q1 and fragmented in Q2.  Specific product ions are selected 




Despite the advantages LC-MS/MS offers, developing a plasma catecholamines 
assay using this technique poses some challenges, specifically the low concentrations of 
catecholamines in human plasma.  Ji et al. (2010) reported that detection of the 
catecholamines (epinephrine and norepinephrine) could not be achieved at the required 
sensitivity because of two major reasons: the assay uses small plasma volumes and 
catecholamines are small, polar, and not easily ionized at the conditions compatible with 
chromatography (14).  In addition, matrix effects due to co-eluting substances in 
biological samples can suppress the ionization of amine-containing compounds including 
catecholamines (15).  For these reasons, it was suggested that derivatization of 
catecholamine samples would be necessary for LC-MS/MS analysis (14). 
 
Derivatization 
Derivatization is the chemical transformation of molecules to improve detection 
and measurement in instruments including LC-MS/MS.  Derivatization of amine-
containing compounds can increase their size, molecular weight, hydrophobicity (non-
polar surface area), and can transform the primary/secondary amine functional groups 
into tertiary amines which are easily protonated (17).  These effects are responsible for 
increased ionization efficiency (IE) and sensitivity.  IE is the ease with which molecules 
in the liquid phase in the MS/MS are transformed to gas phase ions and reach the 
detector.  The increase in IE and sensitivity can be explained as follows: larger molecules 
are more stable and therefore can more easily reach the detector once ionized; increase in 
hydrophobicity allows the derivatives to migrate to the surface of the liquid droplets in 
the ionization chamber, which therefore increases the rate of ionization and the tertiary 
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amines formed are easily protonated due to the increased electronegative induction on the 
nitrogen by the added substituents (17). 
Finding suitable reagents for derivatization can be challenging.  Derivatizing 
agents should encompass some of the following features: ability to introduce or increase 
a permanent charged moiety on the derivative, to yield a derivative that will fragment, 
and to react under mild reaction conditions. Derivatizing agents should have low 
molecular weight (some mass spectrometers have molecular weight detection limits) and 
be of reasonable cost (18).  
Some of the earliest reported derivatization experiments on biogenic amines were 
performed on amino acids in the 1970s.  A common technique was esterification 
(reaction of a carboxylic acid and an alcohol to produce an ester and water) using 
dimethylformamide dimethyl-acetal (DMF-DMA) to produce formamidene esters.  The 
formamidene esters had increased spectral sensitivity in GC-MS (16, 19). This technique 
was later replaced by silyl and N-fluoroacyl ester derivatives, which provided greater 
mass spectral sensitivity enhancement (20).  Recently, derivatization using DMF-DMA 
has been resurrected for use in amino acid analysis using electrospray ionization tandem 
mass spectrometry (ESI-MS/MS) (16).   David et al. (2001) reported that the 
esterification of amino acids using DMF-DMA and n-butanol to produce formamidene 
butyl esters increased the mass spectral sensitivity 20 fold.  Some major strengths of this 
derivatization technique included a short reaction time and high specificity since there 
was no evidence of derivatization of the other functional groups such as hydroxyl, thiol, 
or amides that are found on certain amino acids.  However, the derivatization required 
two steps and some of the reagents were costly (16).    
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Another derivatization technique used on amino acids was acylation.  Acylation is 
an organic reaction used to add an acyl group (RCO) to a compound.  Wen et al. (2006) 
reported acylation of amino acids using N-hydroxysuccinimide-activated N-
alkylnicotinic acid esters (Cn-NA-NHS).  This derivatization technique using Cn-NA-
NHS, which contains a quaternary amine (R4N
+
), aimed to further improve sensitivity by 
increasing the charge on the amine group of the hydrophobic chain.  Sensitivity was 
greatly improved by the combined effects of increased charge on the derivative 
(quaternary amine) and introduction of a larger/longer hydrophobic alkyl chain 
(hydrophobicity).  The same study also observed that increasing the chain length of the 
derivatizing agent Cn-NA-NHS led to increased sensitivity.  Despite the significant 
increase in sensitivity, the technique presented a number of challenges including the time 
required to synthesize the derivatizing reagent Cn-NA-NHS from diclyclohexyl 
caarbodimide, dimethyl formamide, nicotinic acid, and N-hydroxysuccinimide), and the 
cost of the reagents (15).  
In the early 2000s, several scientists reported on stable isotope dimethyl labelling 
for use in proteomics analysis (21, 22, 23).  Guo’s (2007) study on dimethylation via 
reductive amination was one of the most promising reports.  The study described a 
simple, fast, specific, and mild derivatization technique that could be used to improve 
quantification of amine-containing metabolites (23).  This technique involves chemically 
labelling amino acids with isotopically labeled formaldehyde using reductive amination 
to create inexpensive internal standards (IS).  Formaldehyde and isotopically labeled 
formaldehyde (formaldehyde
-13
C, d2- formaldehyde) were used as derivatizing agents in 
the presence of a reducing agent (sodium borohydride) to add stable isotope tags to the 
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amine groups in the metabolites. The labelled isotopes were stable for two weeks at room 
temperature and longer at –20 oC and no byproducts were observed (23).   
Although this labelling technique was used in the preparation of stable 
isotopically labeled amino acids, the same approach could be applied in derivatization 
techniques used to enhance catecholamine sensitivity in LC-MS/MS.  Catecholamines, 
like amino acids, are small, polar, and contain primary and secondary amine groups and 
are therefore expected to react similarly.   
Multiple scientists adopted the Guo et al. (2007) technique in development of 
plasma catecholamine assays (11, 14). Chengjie et al. (2008) reported the successful 
quantification of norepinephrine, dopamine, and neurotransmitters including serotonin, 
and normetanephrine in rat prefrontal cortex micro dialysates using reductive amination.  
The neurotransmitters were derivatized using acetalydehyde-d4 in the presence of sodium 
cyanoborohydride (a reducing agent) in a mild reaction (37 ºC, 25 minutes).  This 
derivatization technique combined with ultra-performance liquid chromatography mass 
spectrometry (UPLC/MS/MS) yielded 20-100 times increased sensitivity (11).   Chengjie 
et al. (2010) also reported ~16-80 fold increased sensitivity for epinephrine and 
norepinephrine derivatized using acetalydehyde-d4 (14).   
Measurement of catecholamines in plasma using LC-MS/MS is still a new 
technique in most clinical laboratories as most assays are still performed using HPLC-
EC.  Some clinical laboratories prefer HPLC-EC analysis of catecholamines because 
sample preparation is more straightforward (no derivatization required) and the oxidation 
vulnerability of catecholamines aids in their measurement using electrochemical 
detectors (24).  Although LC-MS/MS is preferred for its higher specificity and 
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throughput, the main challenge in the development of catecholamines assays using LC-
MS/MS remains their low plasma concentrations and consequent required sensitivity (11, 
14).  With the significant improvement of sensitivity via a reductive amination 
derivatization strategy, the future looks promising for development of assays using this 
technique.   
 
Current research 
The literature suggests that measurement of catecholamines using LC-MS/MS is 
feasible and has multiple advantages compared to HPLC-EC.  Development of a 
catecholamines assay in plasma using LC-MS/MS is currently ongoing at ARUP 
Laboratories.  As mentioned earlier, increasing the sensitivity of catecholamines in the 
mass spectrometer has been the main challenge facing scientists (11, 14).  Derivatization 
using straight-chain aldehydes (acetaldehyde-C2, butyraldehyde-C4, hexanal-C6, and 
octanal-C8) via reductive amination has previously been evaluated to determine the most 
effective aldehydes on sensitivity.   However, a few questions remain on the development 
of this assay: what effect would other types of aldehydes have on sensitivity and what 
other reaction conditions could be evaluated to further increase the sensitivity?  In this 
research, a series of straight-chain and branched-chain aldehydes were evaluated as 
derivatizing agents via reductive amination to analyze their effect on sensitivity.  
Reaction conditions including reagent concentrations and incubation time and 
temperature were also optimized for further sensitivity enhancement.  Method application  










MATERIALS AND METHODS 
 
Chemicals and reagents 
Dopamine hydrochloride, DL-Norepinephrine hydrochloride, (+/-) Epinephrine 
hydrochloride, sodium cyanoborohydride, ammonium acetate (NH4OAc), and sodium 
phosphate (Na2HPO4) were purchased from Sigma Aldrich.  Straight-chain aldehydes: 
propionaldehyde, butyraldehyde, valeraldehyde, hexanal, heptaladehyde, octanal, and 
branched-chain aldehydes: 3, 3- dimethylbutyraldehyde, 2-methylpentanal, 2-
ethylhexanal, hydrocinnamaldehyde, and 3-phenylbutyraldehyde, were also purchased 
from Sigma Aldrich.  Formic acid (98%) was obtained from EMD Millipore Corporation 
and HPLC grade methanol from JT Baker. Clinical reagent water (CLRW) was produced 
in the laboratory using a ThermoScientific pump.   
Individual standard catecholamine samples were prepared as follows: 5 mmol/L 
of dopamine was prepared by dissolving 9.5 mg of dopamine hydrochloride in 10 ml of 
CLRW, 5 mmol/l of norepinephrine was prepared by dissolving 10.2 mg of 
norepinephrine hydrochloride in 10 ml of CLRW, and 5 mmol/L of epinephrine was 
prepared by dissolving 10.9 mg of epinephrine chloride in 10 ml CLRW.  The stock 
solution of each catecholamine was serial diluted to various concentrations used in the 
study and stored in a -70º C for use.  The catecholamines standard was prepared by 
mixing 1 ml of the dopamine, norepinephrine, and epinephrine stocks prepared above. 
The stock solution was serial diluted to different concentrations used in the study and 
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stored in a -70º C for use.   
NH4OAc (200 mmol/L) was prepared by first dissolving 1542 mg NH4OAc in 50 
ml CLRW.  The pH was adjusted using acetic acid to ~ 5.3.  The aqueous solution was 
diluted to 100 ml and stored at room temperature.  Na2HPO4 (20 mmol/L) was prepared 
by dissolving 283.9 mg Na2HPO4 in 100 ml of CLRW and adjusting the pH to 7.2 using 
hydrochloric acid.   
Catecholamines calibrators (standards) for analysis of patient samples were 
prepared in 0.5% acetic acid with 1 mg/ml sodium metabisulfite (AASM).  The stock 
solution was prepared by pipetting AASM (760 µL), dopamine stock (40 µL), 
epinephrine (40 µL), and norepinephrine (160 µL) into a microcentrifuge tube.  The stock 
solution concentration was 200/800 µmol/L (200 µmol/L dopamine/epinephrine and 800 
µmol/L norepinephrine). The calibrator catecholamines concentrations reflect their 
reference intervals in the clinical laboratory.  The stock was serial diluted to the other 
calibrator’s concentrations (CAL 2 -50/200, CAL 3 - 200/800, CAL 4 - 500/2000, CAL 5 
- 5000/20000) pmol/L.  Plain water was used for the blank (calibrator preparation 
protocol adopted from Melissa Hughs PhD., ARUP laboratories).  Low and high quality 
controls were acquired from Bio-Rad laboratories.  Plasma patient samples were acquired 
from the analytic biochemistry laboratory.   
 
Derivatization via reductive amination 
Derivatization was performed by reacting catecholamines with aldehydes in the 
presence of a reducing agent, sodium cyanoborohydride (NaBH3CN).  The samples were 
incubated for 30 minutes at 37ºC and later quenched with formic acid.  In this study, 
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derivatization was accomplished using a generic sample preparation protocol adopted 
from Guo et al. (2007) and modified by Melissa Hughs, Ph.D., ARUP laboratories.  
Ammonium acetate (100 µL, 0.2 M, pH 5.82), dopamine/norepinephrine/epinephrine 
stock (20 µL, 50 nm), sodium cyanoborohydride (25 µL, 0.4 M) prepared fresh daily, and 
aldehyde (20 µL, 1 M in methanol) were pipetted into a 96 well plate format.  The 
aqueous samples were incubated at 37°C for 30 minutes and quenched with formic acid 
(20 µL, 1 M) for 5 minutes at room temperature before injection in the LC-MS/MS 
instrument. 
In the beginning of the study, epinephrine was derivatized using 5 µL neat 
aldehyde per the method adopted from Guo et al. (2007).  Pipetting small volumes was 
challenging and compromised the accuracy and precision of our data.  Therefore, we 
decided to use an aldehyde solution in methanol (20 µL, 1 M in methanol) for the 
dopamine and norepinephrine derivatization reactions.   
Straight-chain aldehydes: propionaldehyde (C3), butyraldehyde (C4), 
valeraldehyde (C5), hexanal (C6), heptaladehyde (C7), octanal (C8), and branched-chain 
aldehydes: 3, 3- dimethylbutyraldehyde (3DB), 2-methylpentanal (2MP), 2-ethylhexanal 
(2EH), Hydrocinnamaldehyde (HC), and 3-phenylbutyraldehyde (3PB), were used as 
derivatizing agents (see Figure 5).  
The catecholamines standards (dopamine, norepinephrine, and epinephrine) were 
derivatized individually in triplicate with each aldehyde on three separate days. The 






Figure 5.  Straight-chain and branched-chain aldehydes 
Aldehydes are organic compounds composed of a carbonyl bonded to a hydrogen 
atom and an R group (alkyl or side chain).  a)  Straight-chain aldehydes are composed 
of a carbonyl with a straight alkyl chain.  b)  Branched-chain aldehydes are composed 





Optimization of a hydrocinnamaldehyde derivatization protocol 
Experiments were carried out to optimize a derivatization protocol for 
hydrocinnamaldehyde, the branched-chain aldehyde that provided the best sensitivity 
(derivatization for hexanal had been completed).  Optimization experiments were 
performed to establish NaBH3CN concentration, hydrocinnamaldehyde concentration in 
methanol, and on incubation time and temperature in that order.  
 
NaBH3CN concentration   
Derivatization of the three catecholamines (in one reaction) was performed at 
different NaBH3CN concentrations.  The other reagent concentrations were similar to the 
generic protocol described above.  Ammonium acetate (100 µL, 200 mmol/L, pH 5.82) 
and catecholamines stock (20 µL, 50 nmol/L) were added to eight different wells of a 96 
well plate format.  NaBH3CN, 25µ L of each concentration (25 mmol/L, 50 mmol/L, 100 
mmol/L, and 400 mmol/L), was added to two of the eight wells (each concentration was 
analyzed in duplicate).   Hydrocinnamaldehyde dissolved in methanol (20 µL of 1000 
mmol/L) was pipetted into the wells.  The aqueous samples were incubated at 37 °C for 
30 minutes and quenched with formic acid (20 µL, 1000 mmol/L) for 5 minutes at room 
temperature.  The samples (20 µL) were injected in an LC-MS/MS system for analysis.   
 
Hydrocinnamaldehyde concentration 
Derivatization of the three catecholamines (in one reaction) was performed at 
different hydrocinnamaldehyde (in methanol) concentrations.  Ammonium acetate (100 
µL, 0.2 mmol/L, pH 5.82), catecholamines stock (20 µL, 50 nm), and NaBH3CN optimal 
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concentration (25 µL, 50 mmol/L) were added to eight different wells in a 96 well plate 
format.  Hydrocinnamaldehyde dissolved in methanol (20 µL) of each concentration (250 
mmol/L, 500 mmol/L, 1000 mmol/L, and 2000 mmol/L) was added to two of the eight 
wells (each concentration was analyzed in duplicate).  The aqueous samples were 
incubated at 37°C for 30 minutes and quenched with formic acid (20 µL, 1000 mmol/L) 
for 5 minutes at room temperature.  The samples (20 µL) were injected in an LC-MS/MS 
system for analysis.   
 
Reaction conditions – time and temperature 
Derivatization of the three catecholamines (in one reaction) was performed at 
different incubation times and temperatures: 25 ºC for 10, 15, and 20 minutes, and 37 ºC 
for 15, 20, and 30 minutes.  Ammonium acetate (100 µL, 200 mmol/L, pH 5.82), 
catecholamines stock (20 µL, 50 nmol/L), NaBH3CN (25 µL, 50 mmol/L), and 
hydrocinnamaldehyde dissolved in methanol (20 µL of 500 mmol/L) were pipetted into 
vials.  A set of two vials were incubated at 25 ºC for each time, 10, 15, or 20 minutes, and 
at 37 ºC for 15, 20, or 30 minutes.  The samples were quenched with formic acid (20 µL, 
1000 mmol/L) for 5 minutes at room temperature.   The samples (20 µL) were injected 
into the LC-MS/MS instrument for analysis.   
 
Comparison aldehydes – hexanal versus hydrocinnamaldehyde 
Catecholamines were derivatized in triplicate using the respective optimized 
protocols for hexanal and hydrocinnamaldehyde.  The hexanal derivatization protocol 
was adopted from Melissa Hughs Ph.D. ARUP Laboratories; ammonium acetate (100 
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µL, 200 mmol/L, pH 5.82), catecholamines stock (20 µL, 50 nmol/L), NaBH3CN (25 µL, 
100 mmol/L), and hexanal dissolved in methanol (20 µL of 1000 mmol/L) were pipetted 
into three wells in a 96 well plate format.  The optimized hydrocinnamaldehyde 
derivatization was performed using the following protocol (from my study); ammonium 
acetate (100 µL, 200 mmol/L, pH 5.82), catecholamines stock (20 µL, 50 nmol/L), 
NaBH3CN (25 µL, 50 mmol/L), and hydrocinnamaldehyde dissolved in methanol (20 µL 
of 500 mmol/L) were pipetted into three wells of the same 96 well plate format.  The 
samples were incubated at 37°C for 30 minutes, and quenched with formic acid (20 µL, 
1000 mmol/L) for 5 minutes at room temperature.  The samples (20 µL) were injected 
into the LC-MS/MS instrument for analysis. 
 
Method application using hydrocinnamaldehyde 
Five repeat plasma patient samples previously analyzed using HPLC-EC and one 
plasma patient pool were derivatized using HC.  A 5 point calibration system 0 pmol/L, 
50/200 pmol/L, 200/800 pmol/L, 500/2000 pmol/L, and 5000/20000 pmol/L (first 
concentration for dopamine and epinephrine, second concentration for norepinephrine) 
was used for quantification.  A 96 weak cation exchange phenomenex plate was first 
conditioned with methanol (1 ml) and later with Na2HPO4 (1 ml, 20 mmol/L).   
Calibrators, controls, and patient samples (500 µL) were pipetted into the plates followed 
by Na2HPO4 (500 µL).  The plates were washed with NH4OAC (1 ml, 10 mmol/L) and 
methanol (1 ml) then dried with nitrogen for 60 seconds.  The catecholamines were 
eluted with 5% formic acid in methanol (2x300 µL) into a 96 well plate.  The eluent was 
dried with nitrogen gas at 37ºC for 20-30 minutes.   
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The precipitated catecholamines were derivatized using an optimized 
hydrocinnamaldehyde derivatization protocol; ammonium acetate (100 µL, 200 mmol/L, 
pH 5.82), catecholamines stock (20 µL, 50 nmol/L), NaBH3CN (25 µL, 50 mmol/L), and 
hydrocinnamaldehyde dissolved in methanol (20 µL of 500 mmol/l) were pipetted into 
the 96 well plate.  The samples were incubated at 37ºC for 30 minutes and later quenched 
with formic acid (20 µL, 1000 mmol/L) for 5 minutes at room temperature.  The samples 




The LC-MS/MS system consisted of an Agilent Technologies HPLC 1260 
Infinity binary system coupled to an ABSCIEX Triple Quad 5500 mass spectrometer.  
Samples (20 µL) were injected into a reversed phase (RP) Phenomenex C18 column (50 
x 2.1 mm, 2.6 µm particle size, 100-Å pore size).  The RP mobile phase A (aqueous) was 
0.1% formic acid in CLRW and mobile phase B (organic) was 0.1% formic acid in 
methanol.  The formic acid, CLRW, and methanol used were LC-MS grade.  Quantitation 
was carried out using ABSCIEX MultiQuant 3.0 software.  
A 17-minute binary gradient elution profile was used for this research project.  
The gradient was set up as follows: t = 0 - 1 minute (99% A, 1% B), t = 1 - 11 minutes 
(5% A, 95% B), t = 11 - 14 minutes (5 A, 95% B), t = 14 - 17 minutes (99% A, 1% B).  
Other chromatography settings were as follows: flow rate = 0.3 ml/min, temperature = 40 
˚C and equilibration time = 0 minutes (gradient adopted from Melissa Hughs, PhD. 
ARUP Laboratories).   
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Mass spectrometry methods  
A MRM mass spectrometry method was determined for each dopamine, 
norepinephrine, and epinephrine derivative before analysis.  The LC-MS/MS was infused 
with a high concentration (250 µmol/L of dopamine, norepinephrine, or epinephrine) 
derivatization solution to optimize the mass spectrometer parameters.  The precursor ion 
for each aldehyde derivative was first identified in quadruple mass spectrometer 1 (Q1 
MS1), then the following parameters were optimized: voltage required to ionize the 
precursor ion in aqueous solution from the HPLC (declustering potential/DP), voltage 
required to move the precursor ion into the collision cell (entrance potential/EP), voltage 
required for fragmentation of the precursor ion into each product ion (this was performed 
for at least five transitions for each catecholamines derivative), and the voltage required 
to move the product ions to the detector (collision exit potential/CEX).  An optimized 
method for each individual catecholamine derivative using the aldehydes was created in 
the mass spectrometer analyst software (see Appendix Tables 12 and 13). 
A MRM mass spectrometry method was developed for hydrocinnamaldehyde 
derivatization optimization and method application experiments (a hexanal 
catecholamines MRM method was adopted from Melissa Hughs, Ph.D. ARUP 
laboratories).  The method was developed using the three catecholamines in one reaction. 
The LC-MS/MS was infused with a high concentration (250 µmol/L) of 
hydrocinnamaldehyde catecholamine derivative solution to optimize the mass 







Dopamine, norepinephrine, and epinephrine were derivatized using C3, C4, C5, 
C6, C7, and C8.  Each derivative was identified by retention time and mass fragmentation 




Formation of mono-alkylated and di-alkylated derivatives was observed for C3 
and C4. C5, C6, and C7 produced only the di-alkylated dopamine derivative.  No 
derivative peaks were observed for C8.  The straight-chain dopamine derivatives had 
similar mass fragmentation patterns to each other.  The three most abundant product ions 
for all the derivatives were 137, 91, and 65 (see Table 1 and Figure 6).  
 
Norepinephrine 
All the aldehydes transformed norepinephrine into a di-alkylated derivative.   
The C6 derivative had the highest sensitivity followed by the C5, C3, and C4derivatives. 
No derivatives were observed for C7 and C8.  The norepinephrine derivatives had 





























Dopamine mono-alkyl derivatives 
Aldehydes Mass 
transitions 
Mean*e4 SD*e4 %CV 
C3 196 / 137 618.71 33.25 3.47 
 196 / 91 405.93 33.56 6.49 
 196 / 65 163.61 12.97 6.30 
C4 210 / 137 31.89 2.62 5.38 
 210 / 91 21.15 2.29 4.79 
 210 / 65 13.85 0.23 0.54 
Dopamine di-alkyl derivatives 
 Mass 
transitions 
Mean*e4 SD*e4 %CV 
C3 238 / 137 360.88 9.77 2.03 
 238 / 91 321.29 10.01 2.33 
 238 / 65 136.55 2.92 1.60 
C4 266 / 137 33.87 4.83 10.76 
 266 / 91 30.12 4.92 12.40 
 266 / 65 11.46 1.95 12.63 
C5 294 / 137 293.42 22.74 5.95 
 294 / 91 252.19 19.17 5.76 
 294 / 158 101.35 7.86 5.88 
C6 322 / 137 899.14 77.46 6.39 
 322 / 91 808.81 57.43 5.09 
 322 / 65 346.91 30.35 6.66 
C7 350 / 137 56.17 6.78 8.52 
 350 / 91 57.09 6.28 9.18 
 350 / 65 23.97 3.74 11.69 
C8 - - - - 
 - - - - 









Figure 6.  Evaluation of derivatized catecholamines using straight-chain aldehydes 
Sensitivity measured in peak area count of derivatized dopamine (a/b), norepinephrine 
(c/d), and epinephrine (e) using straight-chain aldehydes was analyzed.  a)  Only C3 and 
C4 yielded dopamine mono-alkyl derivatives.   b)  The C6 dopamine di-alkyl derivative 
had the highest sensitivity.  c)  No mono-alkyl norepinephrine derivatives were detected.  
d)  The C6 di-alkyl norepinephrine derivatives had the highest sensitivity.  e) The C6 




















Norepinephrine mono-alkyl derivatives 
 Mass 
transitions 
Mean*e4 SD*e4 %CV 
C3 254 / 194 402.46 9.98 2.45 
 254 / 107 302.99 8.52 2.76 
 254 / 77 187.91 4.80 2.55 
C4 282 / 264 162.72 36.43 20.50 
 282 / 137 35.04 8.07 21.15 
 282 / 107 19.35 4.31 20.78 
C5 310 / 292 642.58 52.50 7.87 
 310 / 137 161.72 13.91 8.25 
 310 / 107 165.50 7.34 5.14 
C6 338 / 320 1877.26 180.62 9.78 
 338 / 137 481.60 49.74 10.31 
 338 / 91 133.94 13.90 10.04 
C7 - - - - 
 - - - - 
 - - - - 
C8 - - - - 
 - - - - 




Because epinephrine is a secondary amine, the di-alkylated product was not 
possible. A mono-alkylated derivative was observed with all the aldehydes.  The 




Dopamine, norepinephrine, and epinephrine were derivatized using 3DB, 2MP, 
2EH, HC, and 3PB.  Each derivative was identified by retention time and mass  
 
Table 3.  Straight-chain aldehydes epinephrine derivatization peak area count (n = 9) 
Straight-chain aldehydes 
Epinephrine mono-alkyl derivatives 
 Mass 
transitions 
Mean*e4 SD*e4 %CV 
C3 - - - - 
 - - - - 
 - - - - 
C4 240 / 166 6.04 0.34 5.62 
 222 / 166 4.12 0.36 8.80 
 240 / 137 2.24 0.23 10.45 
C5 254 / 166 16.34 2.19 10.55 
 236 / 166 16.33 2.30 11.89 
 236 / 137 12.85 1.88 11.43 
C6 268 / 166 42.87 1.66 3.80 
 268 / 137 35.05 1.46 4.39 
 250 / 137 34.97 2.16 5.95 
C7 282 / 166 19.63 2.04 8.74 
 282 / 137 17.39 2.62 12.43 
 264 / 166 19.32 2.70 12.57 
C8 296 / 166 27.19 9.71 8.04 
 296 / 137 23.12 8.34 7.84 
 278 / 166 21.77 8.96 9.90 
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fragmentation pattern; peak area counts were determined for the three transitions leading 
to the most abundant ions. 
 
Dopamine 
Formations of mono-alkylated and di-alkylated derivatives were observed for 
3DB, 2MP, 2EH, and 3PB.  HC was the only aldehyde to yield the di-alkylated dopamine 
derivative.  Some of the dopamine derivatives had similar mass fragmentation patterns; 
the 3DB, 2MP, 2EH derivatives most abundant product ions were 137 and 91 while the 
HC and 3PB most abundant product ions were 91 and 137 (see Table 4 and Figure 7). 
 
Norepinephrine 
Formations of mono-alkylated and di-alkylated derivatives were observed for 
3DB and 2MP.  HC and 3PB were the only aldehydes to yield the di-alkylated 
norepinephrine derivative.  No product was observed using 2EH.  The norepinephrine 
derivatives had distinctively different mass fragmentation patterns for each aldehyde (see 
Table 5 and Figure 7). 
 
Epinephrine 
A mono-alkylated derivative was observed for all the aldehydes.  HC and 3PB 
epinephrine derivatives had the largest peak area counts.  The epinephrine derivatives had 






Table 4.  Branched-chain aldehydes dopamine derivatization peak area count (n = 9)  
SDFASDFA Branched-chain aldehydes 
Dopamine - monoalkyl derivatives 
Aldehydes Mass 
transitions 
Mean*e4 SD*e4 %CV 
3DB 238 / 137 3216.79 113.10 3.46 
 238 / 91 2302.53 121.36 5.37 
 238 / 65 975.14 45.81 4.71 
2MP 238 / 137 3223.56 49.59 1.56 
 238 / 91 2248.33 44.29 1.99 
 238 / 119 948.39 18.61 2.00 
2EH 266 / 137 236.26 19.88 8.29 
 266 / 91 163.45 16.98 10.30 
 266 / 65 56.34 5.01 8.87 
HC - - - - 
 - - - - 
 - - - - 
3PB 286 / 137 14.98 14564.49 9.44 
3PB 286 / 91 14.44 13503.25 9.06 
3PB 286 / 65 5.49 4064.24 6.87 
Dopamine - di-alkyl derivatives 
 Mass 
transitions 
Mean*e4 SD*e4 %CV 
3DB 322 / 137 1025.33 57.96 5.90 
 322 / 91 965.79 61.26 6.37 
 322 / 65 397.99 22.96 6.15 
2MP 322 / 137 190.65 11.54 5.91 
 322 / 91 134.51 8.51 6.35 
 322 / 65 52.17 4.57 8.89 
2EH 378 / 137 49.01 6.83 15.14 
 378 / 91 46.55 6.53 14.65 
 378 / 119 14.59 2.08 15.34 
HC 390 / 91 299.55 225.88 4.79 
 390 / 137 205.87 166.46 7.55 
 390 / 254 136.09 114.38 5.26 
3PB 418 / 91 74.43 5.40 7.43 
 418 / 137 64.92 3.94 6.33 








Figure 7.  Evaluation of derivatized catecholamines using branched-chain aldehydes 
Sensitivity measured in peak area count of dopamine (a/b), norepinephrine (c/d), and 
epinephrine (e) using branched-chain aldehydes was analyzed.  a)  3DB, 2MP, 2EH, and 
3PB were the only aldehydes that yielded dopamine mono-alkyl derivatives.   b)  HC was 
the only aldehyde to yield the dopamine di-alkyl derivative.  However, the 3DB 
dopamine di-alkyl derivative had the highest sensitivity.  c)  3DB and 2MP were the only 
aldehydes that yielded norepinephrine mono-alkyl derivatives.   d)  HC and 3PB were the 
only aldehydes to yield the complete norepinephrine di-alkyl derivatives.  2MP and HC 
norepinephrine derivatives had the highest sensitivity.  e)  HC and 3PB epinephrine 






Table 5.  Branched-chain aldehydes norepinephrine derivatization peak area count (n = 9) 
Branched-chain aldehydes 
Norepinephrine mono-alkyl derivatives 
Aldehydes Mass 
transitions 
Mean*e4 SD*e4 %CV 
3DB 254-107 327.57 10.49 3.19 
 254-57 138.92 7.46 5.38 
 254-77 141.57 6.27 4.39 
2MP 254-152 1028.35 26.78 2.60 
 254-107 499.66 13.20 2.70 
 254-135 341.18 10.52 3.07 
2EH - - - - 
 - - - - 
 - - - - 
HC - - - - 
 - - - - 
 - - - - 
3PB 302-91 5245.87 695.39 14.86 
 306-65 1332.41 181.59 15.06 
 302-77 833.17 91.10 11.21 
Norepinephrine di-alkyl derivatives 
 Mass 
transitions 
Mean*e4 SD*e4 %CV 
3DB 338-57 152.33 6.21 4.08 
 338-106 129.96 6.93 5.37 
 338-77 118.80 3.89 3.28 
2MP 254-152 765.05 23.83 3.11 
 254-107 260.18 12.65 4.91 
 254-135 182.62 10.79 5.96 
2EH - - - - 
 - - - - 
 - - - - 
HC 406-388 649.64 36.40 5.56 
 406-91 416.45 14.90 3.54 
 406-137 334.71 18.91 5.68 
3PB 302-91 311.24 25.03 8.19 
 306-65 247.17 25.26 10.27 









Table 6.  Branched-chain aldehydes epinephrine derivatization peak area count (n = 9) 
Branched-chain aldehydes 
Epinephrine mono-alkyl derivatives 
Aldehydes Mass 
transitions 
Mean*e4 SD*e4 %CV 
3DB 250 / 166 38.48 2.69 6.41 
 268 / 166 30.27 2.46 7.72 
 250 / 107 8.24 0.57 6.44 
2MP 268 / 166 28.41 1.96 6.69 
 250 / 166 18.03 1.29 6.60 
 268 / 107 4.60 0.27 5.86 
2EH 296 / 166 4.30 0.38 8.99 
 278 / 166 1.98 0.17 8.35 
 296 / 107 0.73 0.13 14.47 
HC 302 / 137 57.58 4.61 7.90 
 284 / 137 50.22 3.83 7.18 
 302 / 180 41.10 3.37 7.97 
3PB 316 / 137 60.06 7.01 10.45 
 316 / 180 51.10 5.61 10.35 





Optimization of a hydrocinnamaldehyde derivatization protocol 
NaBH3CN concentration 
HC was used to derivatize the catecholamines in one reaction at different 
NaBH3CN concentrations including 25 mmol/L, 50 mmol/L, 100 mmol/L, 250 mmol/L, 
and 400 mmol/L.  The ion corresponding to the mass transition with the largest peak area 
count of each derivative formed at each concentration was analyzed (see Figure 8). 
 
Hydrocinnamaldehyde concentration (in methanol) 
HC was used to derivative the catecholamines in one reaction at different 
concentrations including 250 mmol/L, 500 mmol/L, 1000 mmol/L, and 2000 mmol/L.  
The ion corresponding to the mass transition with the largest peak area count of each  
derivative formed at each concentration was analyzed (see Figure 8).   
 
Time and temperature 
Catecholamines were derivatized using HC in one reaction at 37˚C for 15, 20, and 
30 minutes and at 25˚C for 10, 15, and 20 minutes.  The ion corresponding to the mass 
transition with the largest peak area count of each derivative formed at each time and 
temperature was analyzed (see Figure 8). 
 
Comparison of aldehydes -  hexanal versus hydrocinnamaldehyde 
Catecholamines were derivatized with hexanal (C6) and hydrocinnamaldehyde 
(HC) in one reaction using their optimal sample preparation protocols. Each 








Figure 8.  Hydrocinnamaldehyde derivatization optimization (n = 2) 
NaBH3CN concentration, aldehyde in methanol concentration, and incubation time and 
temperature were evaluated for optimal hydrocinnamaldehyde derivatization conditions.  
The experiments were performed on the catecholamines in one reaction.  a)  The 
HCderivatives sensitivity initially increases with higher NaBH3CN concentration and 
peaks at 50 mmol/L before decreasing.  b)  The HC derivatives sensitivity generally 
decreases with higher aldehyde (in methanol) concentration.  c)  At 25˚C, the HC 
derivatives sensitivity decreases from 10 to 15 minutes and slightly increases at 
incubation time of 20 minutes.  d)  At 37˚C, the HC derivatives sensitivity decreases from 






fragmentation pattern (see Figures 9 and 10); peak area counts were analyzed for the 
most abundant ions (see Table 7 and Figure 11). 
 
Method application using hydrocinnamaldehyde 
HC was used to derivatize one patient pool and five individual repeat patients’ 
samples.  Derivatized catecholamines were identified by retention time and mass 
fragmentation pattern; peak area count was determined for the most abundant mass 
transition.   
Five calibrators including 0 pmol/L, 50/200 pmol/L, 200/800 pmol/L, 500/2000 
pmol/L, and 5000/20,000 pmol/L were used (first calibrator concentration for dopamine 
/epinephrine and second concentration for norepinephrine).  The measured calibrator 
concentrations were compared to the expected values for accuracy (see Table 8) and their 
calibration curves created (see Figure 12).  Quality controls (low and high) and a patient 
pool (analyzed triplicate) were used to evaluate precision (see Tables 9 and 10 ).  The 
five repeat concentrations were compared to the initial concentration for accuracy (see 
















Figure 9.  Hexanal (C6) catecholamines derivatives chromatogram 
C6 was used to derivative catecholamines in one reaction.  The catecholamines retention 
times (RT) were as follows: epinephrine (5.65 minutes), norepinephrine (9.80 minutes), 














Figure 10.  Hydrocinnamaldehyde (HC) catecholamines derivatives chromatogram 
HC was used to derivative catecholamines in one reaction.  The catecholamines retention 
times (RT) were as follows: epinephrine (5.61 minutes), norepinephrine (9.57 minutes), 








Table 7.  Hexanal (C6) versus hydrocinnamaldehyde (HC) catecholamines derivatization 





Mean peak area 
count 
Mean RT SD %CV 
Dopamine 322 / 91 942713.00 9.83 43345.70 4.60 
Norepinephrine 338 / 137 485490.00 9.80 25758.75 5.31 




Mean peak area 
count 
Mean RT SD %CV 
Dopamine 390 / 91 321800.00 9.64 43186.48 13.42 
Norepinephrine 406 / 91 559937.33 9.57 24845.50 4.44 




Figure 11.  Catecholamines derivatization comparison using hexanal (C6) and 
hydrocinnamaldehyde (HC) (n = 3)  
Catecholamines were derivatized in one reaction using HC and C6 optimized 
derivatization protocols.  The C6 dopamine drivative had ~ x3.5 times the sensitivity of 
the HC derivative.  The HC norepinephrine and epinephrine derivatives had higher 












Table 8.  HC method application – expected and observed calibrator concentrations (n = 
1) (ND; not detected) 
 
Dopamine  Norepinephrine Epinephrine 
Expected Observed Expected Observed Expected Observed 
 (pmol/L) (pmol/L)  (pmol/L) (pmol/L)  (pmol/L)  (pmol/L) 
0 0 0 0 0 0 
50 ND 200 136 50 32 
200 ND 800 583 200 154 
500 694 2000 2626 500 585 
















Figure 12.  Method application using hydrocinnamaldehyde (HC) – catecholamines 
standards calibration curves  
Calibrators were analyzed in the method application using HC for patient sample 
concentration quantitation. A)  The dopamine calibrators (50 and 200) pmol/L were not 
detected.  However, the calibration curve was linear at 0 pmol/L, 500 pmol/L, and 5000 
pmol/L (R
2
 = 0.9955).   b)  The norepinephrine calibration curve was linear (R
2
 = 
0.9982).  c)  The epinephrine calibration curve was linear ((R
2








Table 9.  HC method application – controls concentrations and retention times (RT) (n = 
1) 
Hydrocinnamaldehyde derivatized catecholamines controls 
 Low (pmol/L) RT High (pmol/L) RT 
Dopamine 344 9.87 189 9.86 
Norepinephrine 1320 9.80 293 9.84 
Epinephrine 95 5.80 184 5.79 
 
 














1 123.41 9.91 3644.87 9.82 387.62 9.82 
2 292.44 9.94 3372.24 9.81 371.44 9.81 
3 27.10 9.90 3657.51 9.83 373.02 9.83 
Mean 147.65 9.92 3558.20 9.82 377.36 9.82 
SD 134.32 0.02 161.18 0.01 8.92 0.01 











Table 11.  HC method application – method comparison using five plasma patient 




  Initial concentration pmol/L 
(HPLC-EC) 
Repeat concentration pmol/L 
(LC-MS/MS) HC derivatization 
Dopamine 144 48.5 
  <130 ND 
  <130 ND 
  <130 62.5 
  300 766.1 
Norepinephrine 2246 2789 
  2282 897 
  2955 3626 
  4303 4017 
  3192 3585 
Epinephrine 87 97.1 
  371 123.7 
  131 106.7 
  <55 64.8 






It has been reported that reductive amination is a simple, fast, cheap, and mild 
derivatization technique that can significantly improve sensitivity for measurement 
biogenic amines, including catecholamines in LC-MS/MS (23).  Derivatizing 
catecholamines using aldehydes increases sensitivity as follows: they transform 
catecholamines into larger molecules whose protonated forms are more stable and easily 
reach the detector once ionized, they increase the hydrophobicity (nonpolar surface area) 
of the catecholamines which allows them to migrate to the surface of the liquid droplets 
in the ionization chamber, therefore increasing the rate of ionization, and they transform 
the catecholamines into tertiary amines which are easily protonated due to the increased 
electronegative induction on the nitrogen by the added alkyl chains (17).   
In this study, reductive amination of catecholamines was evaluated using a series 
of six straight-chain and five branched-chain aldehydes to determine which was the most 
effective in increasing sensitivity in LC-MS/MS analysis.  The straight-chain aldehydes 
included: propionaldehyde (C3), butyraldehyde (C4), valeraldehyde (C5), hexanal (C6), 
heptaladehyde (C7), and octanal (C8). The branched-chain aldehydes were 3,3-
dimethylbutyraldehyde (3DB), 2-methylpentanal (2MP), 2-ethylhexanal (2EH), 
hydrocinnamaldehyde (HC), and 3-phenylbutyraldehyde (3PB).  The aldehydes were 
used to derivatize, dopamine, norepinephrine, and epinephrine individually in triplicate 
on three different days.  Thereafter, the most effective straight-chain and branched-chain 
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aldehydes were used to derivatize all three catecholamines in one reaction.  
 
Straight-chain aldehydes 
In dopamine derivatization, a mix of the mono-alkyl (one alkyl chain added) and 
di-alkyl (two alkyl chains added) derivatives was observed indicating incomplete 
derivatization.  Dopamine is a primary amine (RNH2) with two hydrogen atoms that can 
be replaced in a derivatization reaction.  C3 and C4 were deemed ineffective for 
dopamine derivatization due to their tendency to form mixed derivatives (mono and di-
alkyls). The longer straight-chain aldehydes including C5, C6, and C7 only yielded di-
alkyl derivatives.  The dopamine C6 derivative had the highest sensitivity (peak area 
count), indicating that C6 was the most effective aldehyde for dopamine derivatization.  
No derivatized products were observed for C8, possibly due to its low solubility in 
aqueous solutions. 
Unlike the dopamine derivatization, all the straight-chain aldehydes successfully 
transformed norepinephrine into the complete di-alkyl derivative.  Norepinephrine is also 
a primary amine (RNH2) with two hydrogen atoms that can be replaced in a 
derivatization reaction.  A possible explanation for this occurrence could be the structural 
difference between dopamine and norepinephrine.  Compared to dopamine, 
norepinephrine has a hydroxyl group on the alpha carbon of the ethylamine chain that 
possibly provides steric hindrance to self-reaction between the electron rich catechol 
group and the imine formed in reductive amination. This limits formation of side 
products and increases reaction efficiency (complete derivatization).  The norepinephrine 
C6 derivative had the highest sensitivity followed by C5, C3, and C4.  The C6 aldehyde 
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appeared to be the most effective aldehydes for norepinephrine derivatization.  No 
derivatives were detected for C7 and C8 that could possibly be due to their low solubility 
in aqueous solutions.   
Unlike the other two catecholamines, epinephrine is a secondary amine (R2NH) 
with one hydrogen atom that can be replaced in a derivatization reaction.  The aldehydes 
successfully transformed epinephrine into the final mono-alky derivative.  Sensitivity 
increased with increase in chain length from C3 to C6 and decreased for C7 and C8, 
which could be due to their low solubility in aqueous solutions.  The C6 derivative had 
the highest sensitivity.   
Hexanal (C6) performed exceptionally and consistently well with all three 
catecholamines and appeared to be the most effective straight-chain aldehyde for 
catecholamine derivatization.  This conclusion was based on the following observations: 
C6 completely converted dopamine and norepinephrine into the final product (di-alkyl 
derivative); C6 converted epinephrine into the final product (mono-alkyl derivative); 
there was low background noise in the C6 chromatograms; the C6 derivatives had 
reproducible peak shapes as seen in the low derivative peak area counts coefficient of 
variation (% CV); and the C6 derivatives had the highest sensitivity for all three 
catecholamines. 
We evaluated LC-MS/MS fragmentation of the straight-chain aldehyde 
derivatives and the aldehyde physical and chemical properties to understand C6’s 
efficiency in catecholamine derivatization.  The dopamine derivatives shared the same 
most abundant product ion (m/z = 137).  The norepinephrine derivatives, however, had 
different abundant product ions.  The epinephrine derivatives shared the same most 
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abundant product ion (m/z = 166).  There was no difference in the C6 derivatives 
fragmentation compared to the other straight-chain aldehydes.  This suggests that 
fragmentation did not play a significant role on the sensitivity.   
This observation also suggests that C6’s physical and chemical properties are 
more favorable for catecholamines derivatization compared to the other straight-chain 
aldehydes.   It has been reported that increasing the chain length of a derivatizing agent 
correlates with higher sensitivity in the LC-MS/MS (15).  The derivatized catecholamines 
sensitivity was higher with longer aldehyde chain length as expected from C3 to C5 and 
peaked with C6.  However, the sensitivity dropped for the C7 and C8 derivatives, which 
conflicts with previous reports.  A reasonable explanation could be the low solubility of 
C7 and C8 in aqueous solutions that would affect their availability in the reaction.  
Therefore, one may suggest that C6 possesses the optimum chain length and solubility for 
the derivatization of catecholamines.  C6’s chain length may provide steric hindrance 
during derivatization, thus limiting formation of side products.   
In reductive deamination derivatization reaction, the carbonyl in the aldehyde is 
converted to an imine (nitrogen double bonded to a carbon) after addition of an alkyl 
chain.  Through transfer of electrons, the primary amine in the catecholamine (in the case 
of dopamine and norepinephrine) is converted to a secondary amine bonded to a partially 
positively charged carbon atom. In one reaction scenario, the electron rich catechol group 
of the catecholamines can easily attack the partially positive carbon and form a cyclized 
bi-product.  However, an aldehyde with a longer alkyl chain in constant motion during 
the reaction can provide steric hindrance to the formation of cyclized bi-products (see 




























































































Figure 13.  Reductive amination using hydrocinnamaldehyde (HC) and hexanal (C6)  
Reductive amination involves the conversion of a carbonyl into an imine which is later 
reduced by the hydride ions from the reducing agent completing the addition of an 
aldehyde alkyl chain.  This figure illustrates the reductive amination mechanism of the 
dopamine (norepinephrine and epinephrine follow the same mechanism).  a) The 
reductive amination proceeds as expected with the action of the reducing agent to 
complete the addition of an aldehyde alkyl chain.  b)  Formation of cyclized byproducts is 
also possible depending on the structural properties of the aldehyde as well as 
concentration of the reducing agent.  Cyclized byproducts tend to form less with C6 and 






and catecholamines present for reaction, leading to incomplete derivatization and lower 
sensitivity.  This theory may explain why we saw an increase in sensitivity with increase 
in chain length from C3 to C6 for most of the catecholamines (the longer the chain, the 
greater the steric hindrance).  Furthermore, the theory may explain why we saw a mix of 
the mono-alkylated and di-alkylated derivatives with the shorter chains (C3 and C4) 
which do not provide sufficient steric hindrance.  
 
Branched-chain aldehydes 
In dopamine derivatization, a mix of the mono-alkyl and di-alkyl derivatives was 
observed, indicating incomplete derivatization.  The branched-chain aldehydes 3DB, 
2MP, 2EH, and 3PB were deemed ineffective due to their tendency to form mixed 
derivatives (mono and di-alkyls).  This may be due to the steric hindrance (access to the 
aldehyde carbonyl) caused by the following: the three methyl groups on the beta carbon 
in 3DB, the methyl group on the alpha carbon in 2MP, the ethyl chain on the alpha 
carbon in 2EH, and the phenyl and methyl groups on the beta carbon in 3PB which limit 
access to their carbonyls leading to incomplete derivatization.  However, the largest steric 
hindrance was possibly observed in 2EH due to its longer ethyl chain on the alpha carbon 
resulting in the lowest derivative sensitivity.  Only HC yielded the complete di-alky 
derivative.  Compared to the other branched-chain aldehydes, HC only has a phenyl ring 
on the beta carbon which is farthest from the carbonyl and consequently has less steric 
hindrance.  
In norepinephrine derivatization, a mixture of mono-alkyl and di-alkyl derivatives 
was observed, indicating incomplete derivatization.  3DB and 2MP were deemed 
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ineffective due to their tendencies to form mixed derivatives (mono and di-alkyls).  No 
derivatives were detected using 2EH.  The large steric hindrance in 3DB, 2MP, and 2EH 
could be a reason for these results. HC and 3PB yielded only the di-alky derivatives due 
to their lower steric hindrance.  
Despite HC’s formation of the complete dopamine and norepinephrine derivatives 
(lower steric hindrance to the aldehyde carbonyl), the 3DB and 2MP derivatives had 
higher sensitivity in general.  This may be explained by HC’s larger molecular volume 
which may cause crowding during the derivatization of dopamine and norepinephrine 
(require addition of two alkyl chains), leading to lower reaction rate (low formation of 
derivatives). The same trend was observed with 3PB, which has a comparable molecular 
volume to HC.   
In epinephrine derivatization, the HC and 3PB derivatives had the largest 
sensitivity followed by 3DB, 2MP, and 2EH.  3DB and 2MP were less effective due to 
their steric hindrance (2 methyl groups on beta carbon) and smaller molecular volume. 
2EH had the lowest effect on sensitivity due to the greater steric hindrance (ethyl group 
on the alpha carbon).  HC and 3PB derivatives have larger molecular volumes, which 
significantly increases their IE.  In addition, epinephrine is a secondary amine with one 
replaceable hydrogen; therefore, there were no overcrowding of added alkyl chains 
compared to the other catecholamines 
Among the branched-chain aldehydes, hydrocinnamaldehyde (HC) was selected 
as the most promising aldehyde for catecholamines derivatization.  This conclusion was 
based on the following observations: HC was the only branched-chain aldehyde to 
effectively transform dopamine and norepinephrine into the final product (di-alkyl 
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derivative), HC converted epinephrine into the final product (mono-alkyl), the HC 
epinephrine derivative had the second largest sensitivity, and the HC derivatives had 
reproducible peak shapes as observed in the low derivative peak area counts % CVs.  
Although the HC dopamine and norepinephrine derivatives did not have the largest 
sensitivity, it was still preferred for its reaction efficiency (no mixed derivatives). 
We evaluated LC-MS/MS fragmentation for the branched-chain aldehydes 
derivatives and the aldehyde physical and chemical properties to understand HC’s 
efficiency in catecholamine derivatization.  HC and 3PB catecholamines derivatives had 
different abundant product ions compared to the other branched-chain aldehydes.  The 
larger molecular volume and lesser steric hindrance (to the aldehyde carbonyl) of HC 
play a role its sensitivity effectiveness and reaction efficiency (complete derivatives).  
Similar to C6, HC’s bulky size and larger molecular volume provides steric hindrance to 
possible formation of cyclized bi-products in reductive amination, leading to higher 
sensitivity and efficiency.  There were no data available on its solubility.  
 
Hydrocinnamaldehyde optimization 
The hydrocinnamaldehyde derivatization protocol using all three catecholamines 
in one reaction was optimized for higher sensitivity.  Experiments were performed to 
optimize NaBH3CN (reducing agent), HC concentration (in methanol), and incubation 
time and temperature.   
NaBH3CN acts as a reducing agent by reducing the imine in reductive amination.  
At low NaBH3CN concentrations, there is a higher chance of imine reduction by the 
electron rich catechol group in the catecholamines, leading to formation of cyclized bi-
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products.   At high NaBH3CN concentrations, there is possibility of side reactions with 
the other reagents due to its reducing potential, which can lead to suppression of the 
derivatized catecholamines in the mass spectrometer and consequently low sensitivity.  
NaBH3CN (50 mmol/L) was selected as the optimal concentration because of the low 
variation in individual catecholamines sensitivity combined with high sensitivity. In 
addition, there was high precision (low % CV) in derivative formation at this 
concentration.  
HC acts as the derivatizing agent by adding its alkyl chain/s to the catecholamines 
amine group.  At very low HC concentrations, the catecholamines react with the aldehyde 
present at different rates, leading to significant variation in sensitivity.  At high 
concentrations, the sensitivity decreases due to the excess aldehyde, which can engage in 
side reactions, leading to less efficiency (incomplete reactions/mixed derivatives).  The 
optimal aldehyde concentration in methanol was 500 mmol/L because of the low 
variation in individual catecholamine sensitivity combined with overall high sensitivity.  
In addition, the highest precision (low % CV) in derivative formation was observed at 
this concentration.  
Incubation time and temperature were optimized for the highest sensitivity.  
Incubation at 25˚C was carried out for 10, 15, and 20 minutes.  There was variation 
observed in individual catecholamine sensitivity at each time and a minor difference in 
the overall sensitivity for the three times.  Incubation at 37 ˚C was carried out at 15, 20, 
and 30 minutes.  There was greater variation in individual catecholamines sensitivity at 
each time compared to 25 ˚C.  The higher temperature possibly increases the rate of 
reaction, which can lead to variation in catecholamines reactions with the aldehyde and 
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consequently sensitivity.  There was also a slight difference in the overall sensitivity 
between the three times.  Despite the greater variation, incubation at 37 ˚C and 30 
minutes was selected as the optimal temperature because of the following reasons: the 
assay measures catecholamines in plasma which is a body fluid, there was a smaller 
variation in individual catecholamine sensitivity coupled with overall high sensitivity, 
and the highest precision (low % CVs) in derivative formation was observed at this time 
and temperature. 
 
Hydrocinnamaldehyde versus hexanal 
HC and C6 were used to derivatize all three catecholamines in one reaction using 
their optimized derivatization protocols.  The C6 dopamine derivative had approximately 
x3.5 more sensitivity compared to the HC dopamine derivative.  The C6 and HC 
derivatives fragmentation did not have any significant differences.  Their transitions led 
to the same abundant product ion (m/z 91) (see Figure 14).  Therefore, other factors 
including reaction conditions, reagent concentrations, incubation time and temperature, 
and solubility may favor C6’s affinity for dopamine.   
The HC norepinephrine and epinephrine derivatives had higher sensitivity 
compared to their C6 derivatives.  The HC MS/MS fragmentations were significantly 
different compared to the C6 derivatives. The HC norepinephrine and epinephrine 
derivatives fragment to one main abundant ion (m/z = 91) while the C6 derivatives 
produce multiple ions of similar intensity (see Figures 15 and 16).  HC’s larger molecular 
volume and hydrophobicity may also explain the increased effect on sensitivity.  








Figure 14.  C6 and HC dopamine derivatives fragmentation 
The C6 and HC derivatives fragment to one main abundant product ion. There is no 













Figure 15.  C6 and HC norepinephrine derivatives fragmentation 
The C6 derivative fragments to multiple ions of similar intensity while the HC derivative 










Figure 16. C6 and HC epinephrine derivatives fragmentation 
The C6 derivative fragments to multiple ions of similar intensity while the HC derivative 




Hydrocinnamaldehyde method application 
An HC method application experiment on five repeat patients’ samples and one 
patient pool was performed to evaluate its sensitivity and use in a clinical setting.  The 
experiment was performed in singlicate.  A five point calibration curve (0, 50/200, 
200/800, 500/2000, 5000/20000) pmol/L was used to analyze the method’s accuracy, 
linearity, and to quantitate patient samples. Controls (low and high) and one patient pool 
which was analyzed in triplicate were used to analyze the method’s precision.  
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The dopamine calibrator derivatives were not detected at lower concentrations (50 
and 200 pmol/L), indicating inadequate lower limit of quantitation (LLOQ).  The 
norepinephrine/epinephrine calibrator derivatives were detected at all the concentrations.  
Although the catecholamines calibration curves appeared to be linear (R
2
 ≥ 0.99), 
multiple calibration curves will need to be studied to confirm the methods accuracy.    
The dopamine controls (low = 344 pmol/L, high = 189 pmol/L) were not within 
the assay’s established ranges (636 – 954 pmol/L) for the low control and (1723 – 2763 
pmol/L) for the high control.  The norepinephrine low control (1320 pmol/L) was within 
range (1094 – 1637 pmol/L) but the high control (293 pmol/L) was not (5752 – 9293 
pmol/L).  Both the epinephrine controls (low = 94.6 pmol/L, high = 184.4 pmol/L) were 
not within the established ranges (325 – 487 pmol/L) for the low and (4342 - 6718 
pmol/L) for the high.  These results may have been possibly compromised due to the lack 
of isotopically labelled internal standards.  In addition, the lack of LLOQ studies may 
explain why dopamine was not detected at the low concentrations.  
The initial patient sample concentrations (analyzed using HPLC-EC) were 
compared to the repeat concentrations obtained using the HC LC-MS/MS method.  Three 
of the initial dopamine concentrations were below the current method’s analytical 
measurement range (AMR) and therefore were not evaluated, while the mean dopamine 
concentration bias was 44.5% for the other two samples.  The mean norepinephrine 
concentration bias was -1.6%.  One initial epinephrine concentration was below the AMR 
and therefore was not evaluated; the mean epinephrine concentration bias for the 
remaining four samples was -17.1%.  The dopamine and epinephrine mean concentration 
biases were not within the current assay’s acceptance criteria (+/- 15%).  
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One plasma patient pool was analyzed in triplicate and the dopamine, 
norepinephrine, and epinephrine concentration s were evaluated for precision.  The 
%CV’s were as follows: dopamine (91.0%), norepinephrine (4.5%), and epinephrine 
(2.4%).  The HC method showed good precision for norepinephrine and epinephrine 
derivatization. 
The HC method application portion of our study had a few limitations.  To 
accurately confirm the method’s accuracy, linearity, and precision multiple experiments 
need to be performed (only one experiment was performed).  In addition, collecting 
patient samples for this study was challenging since most patients provide minimal 
sample volume for the current assay’s analysis.  As a result, the experiment was 
performed using patient samples that had gone through multiple freeze thaw cycles, 
which may have compromised our results.  Lastly, the lack of isotopically labelled 
internal standards (IS) in the optimization of the HC derivatization protocol and HC 
method application experiments may have compromised our results.  IS were not used in 
this study due to their high cost.   
A few more optimization experiments and studies would be required to fully 
optimize the HC method for use in a clinical setting.  For example, optimization 
experiments on reaction conditions including buffers, chromatographic conditions, and 
incubation temperature (> 30 ºC) could be conducted.   
Despite these limitations, our derivatization experiments using 11 aldehydes 
produced precise results as seen in the low % CVs.  The experiments were performed on 




also confirmed that HC could effectively increase the sensitivity of catecholamines in 

















It has been reported that measurement of catecholamines in plasma using LC-
MS/MS is preferred for its high specificity and throughput.  However, development of 
catecholamines assays using LC-MS/MS has been challenging due to their low 
concentrations in plasma.  Scientists have reported that pretreatment of catecholamines is 
required before analysis in LC-MS/MS.  The reductive amination strategy using 
aldehydes was reported as a simple, mild, low cost, and specific technique for 
derivatizing biogenic amines including catecholamines.  In this study, a series of straight- 
chain and branched-chain aldehydes were evaluated to determine the most effective one 
in terms of increase in sensitivity.  C6 and HC were the most effective straight-chain and 
branched-chain aldehydes for catecholamines derivatization.  An HC method application 
using patient samples confirmed its performance in a clinical setting.  However, 
preliminary results indicated that extra optimization experiments are required for higher 
sensitivity.   
We believe that our study confirmed and added to the available information on 
the reductive amination derivatization strategy for increasing LC-MS/MS sensitivity in 
small polar amines.  We are confident that our study will contribute to the development 
of analytical measurement methods of biogenic amines including catecholamines using 







Table 12. Straight-chain aldehydes catecholamines derivatives mass spectrometry 
methods 
 
Straight-chain aldehydes mass spectrometry method parameters  
Dopamine derivatives 
Precursor ion (m/z) Mass transitions DP (v) 
EP 
(v) 
CE (v) CEX (v) 
C3 (mono-alkyl) 
196.0 196.0 / 194.3 120 10 14.65 11.64 
 196.0 / 137.1 120 10 20.32 15.12 
 196.0 / 119.2 120 10 30.11 14.88 
 196.0 / 91.1 120 10 38.11 10.23 
 196.0 / 65.0 120 10 57.57 7.09 
 196.0 / 57.0 120 10 23.85 7.54 
C3 (di-alkyl) 
238.5 238.5 / 209.0 100 10 17.0 10.08 
 238.5 / 137.0 100 10 25.43 15.06 
 238.5 / 119.1 100 10 34.88 12.95 
 238.5 / 91.1 100 10 46.71 10.98 
 238.5 / 73.0 100 10 27.33 16.78 
 238.5 / 65.1 100 10 71.35 7.63 
C4 (mono-alkyl) 
210.1 210.4 / 137.0 80 10 20.75 8.04 
 210.4 / 119.0 80 10 30.92 12.99 
 210.4 / 91.1 80 10 38.72 9.19 
 210.4 / 65.0 80 10 64.05 7.15 
C4 (di-alkyl) 
266.0 266.0 / 137.1 115 10 30.04 14.93 
 266.0 / 130.1 115 10 25.02 13.54 
 266.0 / 119.0 115 10 38.02 12.83 
  266.0 / 91.1 115 10 53.98 10.79 
 266.0 / 65.2 115 10 81.17 6.45 
C5 (mono-alkyl) 
224.2 224.4 / 154.2 260 10 26.31 8.96 
 224.2 / 126.1 260 10 28.45 13.22 
 224.2 / 98.0 260 10 29.04 10.88 
 224.2 / 82.1 260 10 44.21 9.83 
 224.2 / 67.2 260 10 36.17 8.90 
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Table 12 continued     
Precursor ion (m/z) Mass transitions DP (v) 
EP 
(v) 
CE (v) CEX (v) 
 C5 (di-alkyl)    
294.1 294.1 / 158.2 180 10 27.69 9.19 
 294.1 / 137.0 180 10 30.23 8.05 
 294.1 / 119.1 180 10 38.61 13.39 
 294.1 / 91.1 180 10 54.68 10.57 
 294.1 / 65.0 180 10 84.03 13.04 
 C6 (mono-alkyl)    
238.1 238.1 / 236.3 160 10 15.64 13.32 
 238.1 /137.0 160 10 23.04 8.08 
 238.1 / 119.2 160 10 33.78 7.68 
 238.1 / 91.0 160 10 47.10 9.98 
 238.1 / 82.1 160 10 29.92 10.12 
 238.1 / 65.0 160 10 65.93 7.72 
 C6 (di-alkyl)    
322.0 322.0 / 198.3 185 10 29.61 19.30 
 322.0 / 186.2 185 10 30.17 18.43 
 322.0 / 137.1 185 10 33.85 15.77 
 322.0 / 119.0 185 10 42.18 6.95 
 322.0 / 91.1  185 10 60.98 10.01 
 322.0 / 65.0 185 10 90.01 7.09 
 C7 (mono-alkyl)    
252.2 252.2 / 223.3 85 10 14.01 12.87 
 252.2 / 167.3 85 10 20.40 18.31 
 252.2 / 137.2 85 10 24.69 13.16 
 252.2 / 91.2 85 10 51.12 5.25 
 252.2 / 65.1 85 10 74.27 7.16 
 252.2 / 57.1 85 10 35.08 6.93 
 C7 (di-alkyl)    
350.0 350.0 / 321.1 145 10 13.94 10.62 
 350.0 / 137.2 145 10 35.81 7.94 
 350.0 / 119.1 145 10 45.76 13.16 
 350.0 / 91.1 145 10 73.84 10.87 
 350.0 / 65.2 145 10 95.73 7.82 
 350.0 / 57.2 145 10 60.95 9.72 
 C8 (mono-alkyl)    
266.4 266.4 / 237.3 75 10 15.47 21.37 
 266.4 / 137.0 75 10 24.84 14.68 
 266.4 / 118.9 75 10 37.15 14.10 
 266.4 / 91.1 75 10 15.22 10.23 
 266.4 / 64.9 75 10 74.88 28.07 
 C8 (di-alkyl)    
378.3 378.3 / 242.3 150 10 35.90 14.43 
 378.3 / 137.1 150 10 38.60 15.27 
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Table 12 continued      
Precursor ion (m/z) Mass transitions DP (v) 
EP 
(v) 
CE (v) CEX (v) 
 378.3 / 119.0 150 10 45.88 6.85 
 378.3 / 91.1 150 10 66.08 5.19 
 378.3 / 65.2 150 10 107.97 8.23 
Norepinephrine derivatives 
C3 (mono-alkyl) 
212.0 212.0  / 194.0 73 10 15.04 11.58 
 212.0 / 144.2 73 10 18.90 14.21 
 212.0 / 106.9 73 10 36.59 11.97 
 212.0 / 85.9 73 10 10.08 5.19 
 212.0 / 77.0 73 10 59.70 8.06 
 212.0 / 72.0 73 10 23.29 6.46 
C3 (di-alkyl) 
254.1 254.1 / 236.1 120 10 20.90 12.98 
 254.4 / 194.2 120 10 30.04 18.06 
 254.1 / 107.0 120 10 42.76 6.11 
 254.1 / 91.1 120 10 36.14 10.47 
 254.1 / 77.1 120 10 69.73 9.85 
 254.1 / 65.0 120 10 72.90 12.02 
C4 (mono-alkyl) 
226.8 226.8 /159.0 180 10 10.66 16.07 
 226.8 /129.2 180 10 29.92 13.24 
 226.8 / 91.0 180 10 16.95 11.28 
 226.8 / 73.0 180 10 36.47 8.65 
 226.8 / 55.0 180 10 51.24 6.09 
C4 (di-alkyl) 
282.1 282.1 / 264.2 130 10 22.28 8.22 
 282.1 / 137.1 130 10 34.83 8.02 
 282.1 / 128.2 130 10 23.17 13.99 
 282.1 / 107.1 130 10 46.80 12.94 
 282.1 / 91.1 130 10 47.30 11.00 
C5 (mono-alkyl) 
240.4 240.4 / 222.2 80 10 15.56 7.06 
 240.4 / 172.9 80 10 10.32 10.15 
 240.4 / 104.9 80 10 17.06 11.91 
 240.4 / 91.0 80 10 17.95 12.18 
 240.4 / 77.1 80 10 61.34 8.17 
C5 (di-alkyl) 
310.0 310.0 / 292.4 150 10 22.82 9.25 
 310.0 / 137.1 150 10 35.70 15.11 
 310.0 / 107.0 150 10 49.17 6.08 
  310.0 / 91.1 150 10 53.89 10.43 
 310.0 / 77.1 150 10 81.17 8.80 
 310.0 / 77.1 150 10 81.17  
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Table 12 continued 
Precursor ion (m/z) Mass transitions DP (v) 
EP 
(v) 
CE (v) CEX (v) 
C6 (mono-alkyl) 
254.4 254.4 /236.0 90 10 15.23 14.05 
 254.4 / 209.2 90 10 19.27 20.21 
 254.4 / 187.0 90 10 10.26 20.97 
 254.4 / 105.0 90 10 18.04 13.06 
 254.4 / 91.1 90 10 33.55 5.24 
 254.4 / 77.2 90 10 66.56 8.22 
C6 (di-alkyl) 
338.2 338.2 / 320.4 190 10 24.94 10.17 
 338.2 / 224.0 190 10 31.78 13.46 
 338.2 / 137.1 190 10 39.14 13.72 
 338.2 / 91.1 190 10 51.14 10.60 
 338.2 / 77.1 190 10 98.16 8.70 
 C7 (mono-alkyl)     
268.1 268.1 / 250.3 91 10 16.08 8.00 
 268.1 / 107.0 91 10 37.92 11.98 
 268.1 / 91.1 91 10 37.12 5.21 
 268.1 / 77.1 91 10 71.74 8.82 
 268.1 / 57.1 91 10 40.92 6.87 
 C7 (di-alkyl)     
366.1 366.1 / 348.4 176 10 26.91 10.98 
 366.1 / 137.1 176 10 42.34 16.15 
 366.1 / 107.1 176 10 57.01 12.94 
 366.1 / 91.1 176 10 62.25 11.54 
  366.1 / 77.1 176 10 95.95 9.08 
 C8 (mono-alkyl)     
282.5 282.5 / 226.0 80 10  33.34 12.56 
 282.5 / 105.0 80 10 30.70 13.94 
 282.5 / 91.1 80 10 33.96 9.85 
  282.5 / 77.2 80 10 89.16 9.49 
 282.5 / 64.9 80 10 83.92 18.66 
 C8 (di-alkyl)     
394.4 394.4 / 376.3 93 10 29.09 12.12 
 394.4 / 221.0 93 10 13.51 12.88 
 394.4 / 137.1 93 10 45.23 9.73 
  394.4 / 104.8 93 10 33.62 6.26 
 394.4 / 91.1 93 10 40.54 12.27 
 394.4 / 72.0 93 10 47.06 9.43 
Epinephrine derivatives 
 C3 (mono-alkyl)     
226.6 226.6 / 166.1 87 10 26.95 18.0 
 226.6 / 137.1 87 10 28.73 15.56 
 226.6 / 107.1 87 10 37.90 11.9 
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Table 12 continued      
Precursor ion (m/z) Mass transitions DP (v) EP 
(v) 
CE (v) CEX (v) 
 226.6 / 91.0 87 10 15.99 8.61 
208.1 208.1 / 166.2 155 10 25.08 9.49 
 208.1 / 137.1 155 10 27.12 7.93 
 208.1 / 107.1 155 10 34.56 13.54 
 208.1 / 91.1 155 10 40.64 10.10 
 208.1 / 77.0 155 10 62.54 8.65 
 C4 (mono-alkyl)     
240.2 240.2 / 222.1 90 10 18.09 21.6 
 240.2 / 166.1 90 10 28.59 17.42 
 240.2 / 137.0 90 10 30.02 14.90 
 240.2 / 107.0 90 10 40.0 12.11 
 240.2 / 105.0 90 10 17.64 13.0 
 240.2 / 91.0 90 10 44.76 11.07 
 240.2 / 77.1 90 10 67.33 9.70 
222.2 222.2 / 166.1 180 10 26.7 18.0 
 222.2 / 137.0 180 10 27.76 15.5 
 222.2 / 107.0 180 10 37.58 12.09 
 222.2 / 91.0 180 10 41.25 10.79 
 222.2 / 77.1 180 10 66.33 8.66 
 C5 (mono-alkyl)     
254.2 254.2 / 108.1 110 10 25.32 19.14 
 254.2 / 166.1 110 10 29.48 19.0 
 254.2 / 137.1 110 10 29.58 16.79 
 254.2 / 107.1 110 10 40.9 11.79 
 254.2 / 91.1 110 10 49.8 9.82 
 254.2 / 77.1 110 10 73.12 9.59 
236.0 236.0 / 180.1 185 10 22.58 22.18 
 236.0 / 166.1 185 10 27.18 19.80 
 236.0 / 137.1 185 10 27.02 13.81 
 236.0 / 107.0 185 10 38.22 12.08 
 236.0 / 91.1   185 10 41.04 11.59 
 236.0 / 77.1 185 10 66.3 9.20 
 C6 (mono-alkyl)      
268.2 268.2 / 166.2 100 10 30.50 17.00 
 268.2 / 137.1 100 10 30.50 15.50 
 268.2 / 107.1 100 10 42.50 13.00 
250.2 250.2 / 166.2 190 10 28.00 17.00 
 250.2 / 137.1 190 10 29.50 15.00 
 C7 (mono-alkyl)     
282.1 282.1 / 180.1 120 10 28.49 17.23 
 282.1 / 166.1 120 10 31.01 16.0 
 282.1 / 151.0 120 10 39.57 17.95 
 282.1 / 107.1 120 10 43.46 14.0 
66 
 
Table 12 continued      
Precursor ion (m/z) Mass transitions DP (v) EP 
(v) 
CE (v) CEX (v) 
 282.1 / 151.0 120 10 39.57 17.95 
 282.1 / 107.1 120 10 43.46 14.0 
263.9 263.1 / 180.1 171 10 26.42 18 
 263.1 / 166.1 171 10 28.85 18.40 
 263.1 / 151.0 171 10 37.41 15.52 
 263.1 / 137.1 171 10 29.55 13.17 
 263.1 / 135.2 171 10 33.85 16.0 
 263.1 / 107.1 171 10 41.60 11.73 
 C8 (mono-alky)     
296.2 296.2 / 180.0 101 10 29.93 18.43 
 296.2 / 166.0 101 10 33.04 17.62 
 296.2 / 137.1 101 10 34.31 16.16 
 296.2 / 107.1 101 10 45.77 11.59 
 296.2 / 99.1 101 10 51.13 10.76 
 296.2 / 77.1 101 10 86.13 8.87 
278.1 278.1 / 180.1 207 10 27.91 10.04 
 278.1 / 166.1 207 10 31.02 18.01 
 278.1 / 137.1 207 10 31.02 14.02 
 278.1 / 107.7 207 10 42.27 12.45 
 278.1 / 91.1 207 10 52.12 10.42 





Table 13. Branched-chain aldehydes catecholamines derivatives mass spectrometry 
methods 
 
Branched-chain aldehydes mass spectrometry method parameters 
Dopamine derivatives 
Precursor ion (m/z) Mass transitions DP (v) EP (v) CE (v) CEX (v) 
                        3DB (mono-alkyl) 
238.1 238.1 / 137.1 100 10 25.77 16.13 
 238.1 / 119.1 100 10 35.29 14.16 
 238.1 / 102.2 100 10 21.24 6.02 
 238.1 / 91.0 100 10 46.18 10.32 
 238.1 / 65.0 100 10 68.06 7.25 
 3DB (di-alkyl)     
322.4 322.4 / 238.1 190 10 34.84 26.72 
 322.4 / 137.0 190 10 36.43 7.96 
 322.4 / 119.0 190 10 44.75 13.04 
 322.4 / 91.1 190 10 64.80 10.70 
 322.4 / 65.0 190 10 90.90 7.17 
 2MP (mono-alkyl) 
238.1 238.1 /137.1 70 10 23.75 14.44 
 238.1 /119.1 70 10 37.54 14.97 
 238.1 /102.1 70 10 20.15 6.05 
 238.1 / 91.0 70 10 48.74 10.17 
 238.1 / 65.1 70 10 71.64 7.98 
 2 MP (di-alkyl) 
322.1 322.4 / 137.1 140 10 32.60 15.95 
 322.4 / 119.1 140 10 43.79 7.04 
 322.4 / 102.1 140 10 30.99 12.97 
 322.4 / 91.0 140 10 55.51 8.90 
 322.4 / 65.0 140 10 89.82 8.03 
 2 EH (mono-alky) 
266.0 266.0 / 137.2 100 10 28.34 12.94 
 266.0 / 130.0 100 10 20.54 15.02 
 266.0 / 119.3 100 10 36.53 12.89 
 266.0 / 91.1 100 10 53.39 5.30 
 266.0 / 65.0 100 10 71.97 8.90 
 266.0 / 57.2 100 10 34.09 6.79 
 2 EH (di-alkyl) 
378.2 378.2 / 266.2 110 10 30.63 15.85 
 378.2 / 137.1 110 10 38.55 27.93 
 378.2 / 130.1 110 10 23.26 3.94 
 378.2 / 119.1 110 10 55.25 10.88 
 378.2 / 91.2 110 10 65.96 9.93 
 378.2 / 65.0 110 10 116.25 9.13 
 HC (mono-alkyl) 
288.5 288.5 / 270.1 72 10 15.82 24.91 
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Table 13 continued      
Precursor ion (m/z) Mass transitions DP (v) EP (v) CE (v) CEX (v) 
 288.5 / 137.1 72 10 30.78 136.0 
 288.5 / 91.0 72 10 25.71 10.45 
 288.5 / 65.0 72 10 90.79 7.09 
 HC (di-alkyl) 
406.1 406.1 / 388.2 137 10 24.33 12.14 
 406.1 / 180.2 137 10 34.44 16.89 
 406.1 / 137.1 137 10 42.09 15.00 
 406.1 / 119.1 137 10 49.08 14.82 
 406.1 / 91.1 137 10 80.99 10.79 
 406.1 / 65.0 137 10 123.15 7.02 
 3PB (mono-alkyl) 
286.2 286.2 / 198.3 108 10 33.36 23.50 
 286.2 / 137.2 108 10 27.43 13.95 
 286.2 / 91.0 108 10 55.13 11.19 
 286.2 / 65.2 108 10 82.36 7.05 
 286.2 / 57.3 108 10 59.96 6.99 
 3PB (di-alkyl) 
418.2 418.2 / 282.3 166 10 35.93 31.90 
 418.2 / 137.1 166 10 38.45 15.84 
 418.2 / 119.0 166 10 48.73 14.39 
 418.2 / 91.1 166 10 68.97 10.99 
 418.2 / 65.1 166 10 129.12 7.13 
Norepinephrine derivatives 
 3 DB (mono-alkyl) 
254.2 254.2 / 107.0 90 10 41.61 11.99 
 254.2 / 91.2 90 10 34.58 10.99 
 254.2 / 79.1 90 10 54.14 10.00 
 254.2 / 77.0 90 10 67.31 8.88 
 254.2 / 57.2 90 10 47.30 6.90 
 3 DB (di-alkyl) 
338.2 338.2 / 106.9 170 10 54.40 11.23 
 338.2 / 91.0 170 10 68.56 10.83 
 338.2 / 79.2 170 10 78.13 8.89 
 338.2 / 77.1 170 10 92.42 9.77 
 338.2 / 65.0 170 10 98.56 7.26 
 338.2 / 57.0 170 10 67.15 6.31 
 2 MP (mono-alkyl) 
254.3 254.3 / 152.1 110 10 24.82 16.26 
 254.3 / 135.2 110 10 30.65 7.77 
 254.3 / 91.0 110 10 35.34 10.16 
 254.3 / 77.1 110 10 66.05 8.44 
 254.3 / 65.1 110 10 78.09 7.36 
 
 
2 MP (di-alkyl) 
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Table 13 continued 
Precursor ion (m/z) Mass transitions DP (v) EP (v) CE (v) CEX (v) 
338.0 338.0 / 320.3 165 10 24.86 10.10 
 338.0 / 236.0 165 10 32.25 13.86 
 338.0 / 152.0 165 10 37.08 16.03 
 338.0 / 107.1 165 10 53.07 6.19 
 338.0 / 91.1 165 10 64.77 10.54 
 338.0 / 77.1 165 10 89.91 8.26 
 2 EH (mono-alkyl) 
282.2 282.2 / 105.0 82 10 34.96 11.05 
 282.2 / 91.0 82 10 35.93 5.16 
 282.2 / 77.0 82 10 90.05 8.54 
 282.2 / 65.2 82 10 87.21 7.11 
 282.2 / 50.9 82 10 132.88 24.17 
 2 EH (di-alkyl) 
394.2 394.2 / 105.1 130 10 46.72 11.82 
 394.2 / 91.2 130 10 48.00 10.77 
 394.2 / 77.3 130 10 109.2 9.36 
 394.2 / 65.1 130 10 125.62 7.16 
 394.2 / 57.2 130 10 68.67 7.13 
 HC (mono-alkyl) 
288.5 288.5 / 270.1 72 10 15.82 24.91 
 288.5 / 226.8 72 10 8.81 23.13 
 288.5 / 137.1 72 10 30.78 13.60 
 288.5 / 91.0 72 10 25.71 10.45 
 288.5 / 65.0 72 10 90.79 7.09 
 HC (di-alkyl) 
406.1 406.1 / 388.2 137 10 24.33 12.14 
 406.1 / 180.2 137 10 34.44 16.89 
 406.1 / 137.1 137 10 42.09 15.00 
 406.1 / 119.1 137 10 49.08 14.82 
 406.1 / 91.1 137 10 80.99 10.79 
 406.1 / 65.0 137 10 123.15 7.02 
 3 PB (mono-alkyl) 
302.0 302.0 / 166.1 120 10 23.21 17.85 
 302.0 / 137.0 120 10 33.68 8.08 
 302.0 / 77.1 120 10 84.06 8.72 
 302.0 / 65.0 120 10 87.36 7.09 
 3 PB (di-alky) 
434.1 434.1 / 180.2 175 10 35.95 10.23 
 434.1 / 137.1 175 10 43.26 7.97 
 434.1 / 105.1 175 10 73.26 12.07 
 434.1 / 77.1 175 10 127.05 8.94 
 434.1 / 65.0 175 10 137.93 7.03 
Epinephrine derivatives 
 3 DB 
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Table 13 continued      
Precursor ion (m/z) Mass transitions DP (v) EP (v) CE (v) CEX (v) 
 268.0 / 166.3 140 10 30.74 17.53 
 268.0 / 128.1 140 10 30.90 16.83 
 268.0 / 105.1 140 10 36.07 11.43 
 268.0 / 91.0 140 10 36.58 10.33 
250.0 250.0 / 166.1 190 10 29.00 9.06 
 250.0 / 107.1 190 10 42.91 11.58 
 250.0 / 91.2 190 10 53.09 7.43 
 250.0 / 79.2 190 10 53.10 8.33 
 250.0 / 77.1 190 10 72.07 8.20 
 2 MP 
268.0 268.0 / 180.0 108 10 25.79 10.24 
 268.0 /166.0 108 10 27.98 9.42 
 268.0 / 137.1 108 10 31.62 8.00 
 268.0 / 107.1 108 10 43.80 12.07 
 268.0 / 91.1 108 10 50.27 10.87 
250.0 250.0 / 180.0 180 10 23.31 19.09 
 250.0 / 166.1 180 10 26.42 9.68 
 250.0 / 137.1 180 10 28.77 7.85 
 250.0 / 107.0 180 10 39.97 6.15 
 250.0 / 91.1 180 10 49.70 10.55 
 2 EH 
296.0  296.0 / 180.0 100 10 26.85 19.21 
 296.0 /166.0 100 10 30.30 16.84 
 296.0 /151.0 100 10 40.71 15.13 
 296.0 /137.1 100 10 34.73 14.06 
 296.0 /123.1 100 10 64.35 13.00 
 296.0 /107.0  100 10 45.32 12 
278.0 278.0 / 180.0 177 10 24.85 10.32 
 278.0 / 166.0 177 10 27.55 17.64 
 278.0 / 151.1 177 10 37.49 15.23 
 278.0 / 131.1 177 10 45.44 14.63 
 278.0 / 123.0 177 10 60.70 13.39 
 278.0 / 107.1 177 10 42.77 12.60 
 HC 
302.0 302.0 / 180.0 110 10 27.51 18.59 
 302.0 / 166.1 110 10 34.50 9.48 
 302.0 / 151.1 110 10 30.53 8.85 
 302.0 / 137.1 110 10 33.92 15.97 
 302.0 / 119.1 110 10 44.31 6.97 
 302.0 / 107.1 110 10 46.97 6.08 
284.0 284.0 / 180.0 182 10 25.43 19.10 
 284.0 / 166.1 182 10 31.07 9.26 
 284.0 / 151.1 182 10 29.77 16.88 
 284.0 / 137.1 182 10 30.39 14.58 
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Table 13 continued      
Precursor ion (m/z) Mass transitions DP (v) EP (v) CE (v) CEX (v) 
 284.0 / 107.1 182 10 44.63 6.05 
 3 PB 
316.0 316.0 / 180.0 133 10 25.44 18.82 
 316.0 / 151.2 133 10 30.56 16.83 
 316.0 / 137.1 133 10 33.17 14.14 
 316.0 / 119.1 133 10 45.89 6.81 
 316.0 / 105.1 133 10 44.45 6.10 
 316.0 / 103.1 133 10 69.63 5.84 
298.0 298.0 / 180.2 190 10 23.33 17.99 
 298.0 / 151.2 190 10 28.42 14.56 
 298.0 / 137.1 190 10 30.92 7.85 
 298.0 / 119.1 190 10 41.75 14.17 
 298.0 / 105.1 190 10 39.94 13.09 
































Table 14. Hydrocinnmaldehyde catecholamines derivatives mass spectrometry methods 
 
Hydrocinnamaldehyde mass spectrometry method parameters 
Dopamine derivative 
Precursor ion  
 Mass transitions DP (v) EP (v) CE (v) CEX (v) 
390.1 390.1 / 91.1 173 10 70.20 10.89 
 238.1 / 65.0 173 10 104.98 7.00 
 390.1 / 137.1 173 10 37.74 16.82 
 390.1 / 119.1 173 10 43.95 12.46 
Norepinephrine derivative 
388.1 388.1 / 91.1 226 10 81.22 10.87 
 388.1 / 65.1 226 10 125.79 7.76 
 388.1 / 137.1 226 10 40.32 15.88 
 388.1 / 180.2 226 10 33.93 18.95 
406.3 406.3 / 91.1 170 10 83.89 10.66 
 406.3 / 65.1 170 10 122.34 7.04 
 406.3 / 137.2 170 10 42.76 7.67 
 406.3 / 180.0 170 10 34.90 10.31 
Epinephrine derivative 
302.2 302.2  / 91.1 140 10 61.95 11.15 
 302. 2 / 65.1 140 10 94.39 7.17 
 302.2  / 137.2 140 10 34.01 17.00 
 302.2 / 180.0 140 10 27.0 10.27 
284.1 284.1  / 91.1 190 10 53.94 10.90 
 284.1 / 65.1 190 10 83.95 7.38 
 284.1 / 137.2 190 10 30.28 8.08 
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